Welcome to our dedicated page for Inventiva S.A. SEC filings (Ticker: IVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inventiva S.A. filings document a foreign private issuer and ADR program tied to a clinical-stage biopharmaceutical company developing oral therapies for MASH. Form 6-K reports furnish press releases and meeting notices covering lanifibranor development, annual and preliminary financial results, R&D expense trends, cash resources, revenues, and financing activity.
The company's regulatory disclosures also cover governance and shareholder voting matters, annual general meeting materials, leadership and organizational changes, material agreements, capital-structure disclosures, and portfolio actions including the completed sale of odiparcil. These records connect Inventiva's drug-development focus with its reporting obligations as a France-based issuer listed through American depositary shares.
Inventiva S.A. is convening an ordinary and extraordinary general meeting on June 30, 2026 in Paris and sets out extensive resolutions on 2025 results, governance and future financing tools. Shareholders are asked to approve 2025 statutory and consolidated accounts showing a net accounting loss of EUR 207,965,630.56, to carry this loss forward, bringing the debit balance of retained earnings to EUR 583,594,899.42, and to confirm that no dividend will be paid. The agenda includes say‑on‑pay approvals, renewal and appointment of directors, and a board fee pool of up to EUR 1,500,000. Shareholders are also asked to authorize a share buyback of up to 10% of outstanding shares at a maximum price of EUR 40 per share and to grant multiple capital authorization mandates, including share issues with and without preemptive rights up to a combined nominal cap of EUR 2,000,000 and related debt securities up to EUR 500,000,000. Further resolutions cover employee and officer equity incentives, an at‑the‑market program framework, and potential capital reductions via share cancellations. One resolution notes that shareholders’ equity has fallen below half of share capital and records the decision not to dissolve the company, requiring equity to be restored within the legal timeframe.
Inventiva S.A. ownership disclosure: Deep Track entities and David Kroin report beneficial ownership of 7,800,465 ordinary shares, representing 3.76% of the class as of March 31, 2026. The filing says the position is calculated using 207,707,475 shares outstanding as of that date.
The reported holdings comprise 6,578,012 Ordinary Shares, 1,222,453 ADS (each ADS = 1 Ordinary Share) and 9,999,999 Warrants exercisable at €1.50 subject to a T3 Triggering Event. The T3 Triggering Event requires topline NATiV3 endpoint results by June 15, 2027; warrant exercise must occur no later than July 30, 2027. The filing is a joint Schedule 13G/A amendment signed May 15, 2026.
Inventiva S.A. filed a Form 6-K to share leadership changes as it advances its MASH program. The company appointed Axel-Sven Malkomes as Chief Financial Officer, Susan Coles as Chief Legal Officer, and Pamela Herbster as Chief People Officer.
These executives bring extensive experience in investment banking, biopharma finance, legal, governance, and human resources, including prior roles tied to major M&A and capital markets transactions. Inventiva is preparing for the top-line data readout from its NATiV3 Phase 3 trial of lanifibranor in MASH, expected in the fourth quarter of 2026.
Existing leaders Jean Volatier and Nathalie Harroy will remain with the company in new roles, supporting finance, corporate social responsibility, and human resources as Inventiva plans for potential regulatory submissions and commercialization.
Inventiva S.A. files its 2025 annual report highlighting heavy losses, tight liquidity and dependence on its lead drug lanifibranor for MASH. Ordinary shares outstanding were 193,236,978 as of December 31, 2025. The company reported net losses of €354.1 million in 2025, €184.2 million in 2024 and €110.4 million in 2023, reflecting intensive R&D and financing costs.
As of December 31, 2025, Inventiva held €99.3 million of cash and cash equivalents and €131.6 million of short-term deposits, but warns these resources only fund operations until the middle of the first quarter of 2027, raising substantial doubt about its ability to continue as a going concern. Additional funding is required, potentially through equity, debt, structured financings and royalty deals, all of which may be dilutive or expensive.
The report details significant obligations, including two €25 million EIB tranches due in December 2026 and January 2027, CRO and CMO contracts, and royalty certificates that entitle investors to 2–3% of future net sales of lanifibranor until 2038. Strategically, Inventiva has halted all pre-clinical research, cut its workforce by slightly more than 50%, and now focuses exclusively on completing Phase 3 development and potential commercialization of lanifibranor in an increasingly competitive MASH market.
New Enterprise Associates–affiliated funds report beneficial ownership of 9,372,390 Inventiva S.A. ordinary shares, equal to 4.9% of the class. This Amendment No. 4 to Schedule 13D is being filed because the reporting group fell below the 5% reporting threshold after an increase in Inventiva’s outstanding shares.
NEA 17 holds 6,684,064 ordinary shares plus 1,021,660 Exercisable Shares from T1 BSAs, T1bis BSAs and Pre-Funded Warrants, while GEO holds 1,666,666 ordinary shares and may be deemed to share in the same Exercisable Shares. The group states it acquired the position for investment purposes, reports no transactions in the last 60 days, and disclaims beneficial ownership beyond shares held of record.
Inventiva reported 2025 full-year results showing revenues of €4.5 million, down from €9.2 million in 2024, and a net loss widening to €354.1 million from €184.2 million. Cash and cash equivalents were €99.3 million and short-term deposits €131.6 million as of December 31, 2025.
The company raised gross proceeds of $172.5 million in a U.S. public offering and €115.6 million from the second tranche of a structured financing, helping extend its cash runway, which it estimates to last until the middle of the first quarter of 2027. Auditors will include a section on material uncertainty related to going concern in their report.
R&D expenses fell 4% to €87.0 million, while general and administrative costs jumped to €47.9 million, driven largely by €20.3 million of share-based compensation linked to governance and organizational changes. A €212.8 million net financial loss, mainly from non-cash fair value adjustments on derivative instruments and warrants, significantly contributed to the overall loss.
Andera Partners and affiliated investors report a 7.7% beneficial stake in Inventiva S.A., totaling 14,114,476 ordinary shares as of December 31, 2025. The shares are held through BioDiscovery 6 FPCI, which owns 12,296,295 ordinary shares and 1,818,181 American Depositary Shares, each ADS representing one ordinary share.
Andera Partners is the management company of BioDiscovery 6, and its managing partners, Stephane Bergez and Francois Xavier Mauron, may be deemed to share voting and dispositive power over these securities. The filers certify the holdings were not acquired to change or influence control of Inventiva.
Inventiva S.A. reported an updated ownership disclosure from Sofinnova-affiliated investors. As of December 31, 2025, Sofinnova Crossover I SLP beneficially owns 8,433,227 ordinary shares, corresponding to 12,332,804 voting rights, representing 5.6% of Inventiva’s 221,065,508 voting rights outstanding as of January 31, 2026.
Sofinnova Crossover II SLP holds 6,753,246 ordinary shares and voting rights, or 3.1% of voting rights. Sofinnova Partners SAS, as management company of both funds, together with investment committee members Antoine Papiernik, Cedric Moreau, Kinam Hong, Joseph Anderson and Jacques Theurillat, are each reported with 15,186,473 shares and 19,086,050 voting rights, or 8.6% of voting rights.
The individuals state that this report should not be construed as an admission that they are beneficial owners of the securities for Section 13(d) purposes.
Inventiva S.A. received an updated ownership report showing that Great Point Partners, LLC, together with Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, beneficially owns 6,783,269 ordinary shares, representing 3.49% of the company’s share class.
This total includes 3,449,937 shares of common stock held outright and warrants to purchase a further 3,333,332 shares of common stock, all treated as beneficially owned. The filers report no sole voting or dispositive power, instead sharing both voting and disposal power over all reported shares, and state that the holdings are not intended to change or influence control of Inventiva.
Inventiva S.A. reported certain preliminary, unaudited figures for 2025, highlighting a strengthened cash position following major financings. As of December 31, 2025, cash and cash equivalents were €99.3 million and short-term deposits were €131.6 million, supporting the company’s MASH-focused clinical pipeline.
Net cash used in operating activities rose to (€104.6) million from (€85.9) million, driven by pipeline prioritization, lower licensing revenues from CTTQ, and higher general and administrative expenses, while R&D expenses decreased slightly to €86.9 million from €90.9 million. Net cash used in investing activities was (€133.2) million, mainly from new short-term deposits.
Net cash generated by financing activities reached €241.1 million, including €115.6 million of gross proceeds from the second tranche of a structured financing and $172.5 million of gross proceeds from a U.S. public offering. Revenues declined to €4.5 million from €9.2 million in 2024. Based on its current plan, Inventiva estimates its cash, cash equivalents, and short-term deposits can fund operations until the middle of the first quarter of 2027, with a potential extension to the middle of the third quarter of 2027 if Tranche 3 warrants are fully exercised.